- Poster presentation
- Open Access
Influence of growth hormone receptor exon 3 polymorphism on growth response in children with growth hormone deficiency
© Yang and Hwang; licensee BioMed Central Ltd. 2015
Published: 28 April 2015
Pharmacogenetic effects of recombinant human growth hormone according to growth hormone receptor (GHR) exon 3 polymorphism (fl vs. d3) were controversial. We investigated growth hormone response in children with growth hormone deficiency (GHD).
Total 58 prepubertal children (31 boys and 27 girls) with GHD were enrolled in this study. Subjects were divided to 2 groups according polymorphism (fl/fl, n=48; fl/d3 and d3/d3, n=10), and compared baseline phenotypes and the first year growth response to growth hormone treatment.
The distribution of GHR exon 3 isoforms in children with GHD demonstrated that the frequency of fl/fl (82.8%) is higher than that in most of European studies. There was no significant difference in baseline height SDS between 2 groups. Height velocity during the first year of growth hormone replacement therapy tended to be higher in subjects who have d3 allele (fl/d3 and d3/d3), but there was no statistical difference according to genotype.
It seemed that d3 allele of GHR exon 3 had no impact on the baseline phenotype and growth hormone response in patients with GHD. Relationship between GH dose and IGF-1% to help fully elucidate the value of IGF-1 testing in GH treatment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.